Anthem Biosciences Limited (ANTHEM) breaks below support, falling -5% to ₹746.1 on the NSE on 22 Jul 2026, backed by the recent investor presentation announcement on July 21, 2026. The stock’s decline today appears to be a reaction to the presentation, where the company discussed its strategic direction and financial performance amidst market uncertainties. This move is somewhat isolated to Anthem, as the broader biotech sector remains stable.

Technical setup — trendlines & DMA

From a technical perspective, Anthem Biosciences is currently in a breakdown phase, having fallen below its 6-month support trendline of ₹757.3. The stock is now trading 1.50% below this support level, indicating a potential shift in short-term momentum. Resistance remains at ₹810.61, which is 8.65% above the current price. The 50-day moving average (DMA) at ₹770.8 is above the 200-DMA at ₹701.3, suggesting a bullish underlying trend, though the stock is currently trading below both moving averages. In terms of its 52-week range, the stock is positioned in the middle third, 57% above the 52-week low and 14.6% below the 52-week high, indicating that a significant portion of its potential upside may already be priced in.

Fundamentals & business context

On the fundamental front, Anthem Biosciences presents a mixed picture. With a PE ratio of 74.6 and profit margins of 27.8%, the stock appears richly valued relative to its earnings. However, its revenue CAGR of 26.2% over the past five years suggests strong growth potential. The company’s institutional holding of 12.3% indicates a level of confidence from sophisticated investors, though it is not overwhelmingly high. There was no specific NSE catalyst today beyond the investor presentation, which may have contributed to the stock’s decline as investors digested the information provided.

Algorithmic scorecard

The overall algorithmic scorecard for Anthem Biosciences reflects a technically strong but fundamentally weaker profile. Two of the strongest signals are the company’s excellent revenue CAGR of 26.2%, indicating robust growth, and its very low debt levels with a D/E ratio of 0.00, showcasing strong financial health. On the flip side, the stock’s overvaluation with a PEG ratio of 4.84 and negligible dividend yield of 0.26% are significant weaknesses. The overvaluation suggests that the stock may be pricing in future growth that has not yet materialized, while the low dividend yield offers little income to investors, making the stock less attractive from an income perspective.

Company outlook

Management’s forward guidance for Anthem Biosciences is optimistic, with aspirations to maintain a historical growth rate of upwards of 20%. They anticipate growth in the GLP-1 market as an alternative to Chinese imports and aim for a 20% growth in the specialty ingredients business. The ramp-up of newly launched commercial molecules is expected over the next two to three years. Additionally, the company is open to acquisitions in India and abroad if they align with their strategic goals. This outlook suggests a focus on both organic growth and strategic acquisitions to drive future performance.

Get all details on ANTHEM — P&L, peers, shareholding and more on TradeAlone.

Anthem Biosciences Limited (NSE: ANTHEM) has announced an investor presentation scheduled for July 21, 2026. This event aims to provide detailed insights into the company’s strategic direction and financial performance. The presentation will cover forward-looking statements and the company’s ability to implement its growth strategy, despite market risks and uncertainties.

Financial Highlights for Q1FY27

The consolidated financial highlights for Q1FY27 reveal a robust business performance. The company reported consolidated revenues from operations of ₹4,182 Mn for the quarter. The CRDMO business delivered revenues of ₹3,408 Mn, while the specialty ingredients segment generated ₹774 Mn in revenues. The EBITDA stood at ₹1,755 Mn, with margins at 39.6%. The profit after tax (PAT) was ₹1,199 Mn, with PAT margins at 27.1%. The net cash position as of June 30, 2026, is ₹17,197 Mn.

Message from Leadership

Ajay Bhardwaj, Chairman, MD & CEO, emphasized the company’s commitment to sustaining revenue growth aligned with its long-term historical performance. He noted the timing shifts in deliveries to key customers but assured that the underlying demand remains strong. Bhardwaj highlighted the year-on-year improvement across both EBITDA and PAT margins, attributing this to disciplined focus on cost efficiencies, yield optimization, and employee productivity.

Anthem Biosciences Limited remains optimistic about capturing momentum in the latter half of the year and sustaining its industry-leading margin profile through the year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Anthem holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 4.84 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 27.8% reflect exceptional pricing power and operational efficiency. Buyers show up with 1.8x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.84 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.

Anthem Biosciences Limited (NSE: ANTHEM) showcased a robust performance in its Q1FY27 investor presentation, highlighting strong business fundamentals and promising future growth. The company reported consolidated revenues of ₹4,182 million for the quarter, with a notable focus on maintaining its industry-leading margin profile. The CRDMO business delivered ₹3,408 million in revenues, while the Specialty Ingredients segment contributed ₹774 million. EBITDA stood at ₹1,755 million with margins at 39.6%, and PAT was ₹1,199 million with margins at 27.1%.

Strong Business Performance

The underlying demand remains strong, with a higher concentration of scheduled deliveries in the latter half of the year. The company is well-positioned to capture this momentum, as stated by Chairman, MD, and CEO Ajay Bhardwaj. The disciplined focus on cost efficiencies, yield optimization, and employee productivity continues to reinforce the company’s margin profile.

Robust Margins and Financial Health

Anthem Biosciences Limited’s EBITDA margin improved year-on-year, reflecting disciplined cost management and yield optimization. The company’s net cash position as of June 30, 2026, stood at ₹17,197 million, underscoring its strong financial health. The return on equity (ROE) and return on capital employed (ROCE) for Q1FY27 were 15.4% and 23.3%, respectively, indicating robust returns. The gross fixed assets turnover and net cash to EBITDA ratio were 2.45x and 4.0x, respectively, highlighting efficient asset utilization and strong liquidity.

Forward-Looking Outlook

Anthem Biosciences Limited remains committed to sustaining revenue growth aligned with its long-term historical performance. With a strong pipeline of commercial and late-stage molecules, the company is well-positioned to drive future growth and maintain its leading margin profile.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Anthem holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 4.94 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 27.8% reflect exceptional pricing power and operational efficiency. Buyers show up with 1.8x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.94 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.